miR-425-5p promotes cell proliferation, migration and invasion by directly targeting FOXD3 in hepatocellular carcinoma cells

HEWEN WU, JIA SHANG, WEILI ZHAN, JUNPING LIU, HUIBIN NING and NING CHEN

Department of Infectious Disease, Henan Key Laboratory for Liver Disease, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China

Received September 9, 2018; Accepted April 25, 2019

DOI: 10.3892/mmr.2019.10427

Abstract. MicroRNAs (miRs) are important regulators of the tumorigenesis and metastasis of various cancers. In the present study, the roles and underlying mechanisms of miR-425-5p in the development of hepatocellular carcinoma (HCC) were investigated. RT-qPCR analysis revealed that miR-425-5p was upregulated in HCC tissues and cell lines. A functional study in vitro using MTT assays, colony formation and Transwell assays demonstrated that overexpression of miR-425-5p promoted the proliferation, migration, and invasion of HCC cells, prevented cell apoptosis and accelerates the epithelial-mesenchymal transition process, whereas miR-425-5p knockdown induced opposing effects. A further mechanistic study revealed that forkhead box D3 (FOXD3) was a direct target of miR-425-5p, and gain- and loss-of-function of FOXD3 studies demonstrated that FOXD3 suppressed HCC cell proliferation, migration, and invasion. Furthermore, rescue experiments revealed that overexpression of FOXD3 counteracted the positive effects of miR-425-5p on HCC malignant behaviors. Collectively, the present results demonstrated that miR-425-5p promotes HCC cell proliferation, migration and invasion by directly targeting FOXD3 expression, potentially providing a novel target for the treatment of HCC.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common human cancers globally and the second leading cause of cancer-associated mortality (1). At present, the major treatment strategies for HCC are early detection, surgical resection, liver implantation and gene therapy (1). Despite major advances in the diagnosis and treatment of HCC, the 5-year survival of patients with HCC remains poor due to the high incidence of cancer recurrence and metastasis (1). Therefore, it is urgent to investigate the molecular mechanisms underlying HCC development. A number of reports have indicated that microRNAs (miRNAs/miRs) serve important roles in HCC carcinogenesis (2-16).

miRNAs are ~22-nucleotide, small, noncoding RNAs that can post-transcriptionally regulate target gene expression via complementary base pairing to block the translation or promote the degradation of target mRNAs (17). miRNAs have been implicated in various physiological and pathological processes, including cell differentiation, embryonic development and carcinogenesis (18). Increasing evidence demonstrates that dysregulated miRNAs are involved in the development and progression of a variety of cancers, including HCC (2). For example, miR-199-3p, an miRNA reported to be downregulated in HCC, can inhibit tumorigenesis of HCC cells by targeting zinc fingers and homeoboxes protein 1/p53-upregulated modulator of apoptosis signaling, vascular endothelial growth factor (VEGF)/a, VEGF receptor (VEGFR)1, VEGFR2, hepatocyte growth factor, matrix metalloproteinase-2, yes-associated protein 1 and CD151, and increasing the doxorubicin sensitivity of human HCC cells by regulating mTOR and c-Met (3-9). Furthermore, miR-199-3p was demonstrated to efficiently inhibit tumor growth in a transgenic mouse model of HCC and an HCC tumor-bearing nude mouse model (10,11). A recent report revealed that miR-501-3p was downregulated in metastatic HCC cell lines and tissue samples from patients with recurring and metastasized HCC, and its expression was associated with tumor progression and poor prognosis in patients with HCC; further mechanistic study revealed that lin-7 homolog A mediated the suppressive effects of miR-501-3p on the metastasis and progression of HCCs (12). Recent studies also revealed that HCC cell-derived exosomal miRNAs serve important roles in HCC development, particularly in metastasis (13-16). For example, tumor-derived exosomal miR-25-5p promoted tumor self-seeding by enhancing the invasive and migratory abilities of recipient HCC cells (14). Hepatoma cell-secreted miR-103 increased vascular permeability and promoted metastasis by directly inhibiting the expression of

Correspondence to: Dr Hewen Wu, Department of Infectious Disease, Henan Key Laboratory for Liver Disease, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, 7 Weiwu Road, Zhengzhou, Henan 450003, P.R. China
E-mail: hewenwu1973@126.com

Abbreviations: miRNA/miR, microRNA; FOXD3, forkhead box D3; HCC, hepatocellular carcinoma

Key words: HCC, miR-425-5p, FOXD3, HCC cell malignant behaviors, cell apoptosis
VE-cadherin, p120-catenin and zonula occludens 1 (15). It has been reported that miR-425-5p expression was dysregulated in various cancers, including gastric cancer, HCC, cervical cancer, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, renal cell carcinoma and melanoma, and that the altered expression of miR-425-5p is associated with the pathogenesis and progression of cancer (19-26); however, the roles and mechanisms of miR-425-5p in the development of HCC are yet to be determined.

Forkhead box D3 (FOXD3) is a member of the forkhead box family of transcription factors. The forkhead box proteins are characterized by a distinct conserved ‘forkhead’ or ‘winged helix’ DNA-binding domain (27). FOXD3 is an important stem cell factor expressed in various types of stem cells and has an established role in development (28). Various studies have reported that FOXD3 is also involved in the development of a number of cancers (29-37); however, reports into its roles and mechanisms in HCC are limited.

In the present study, the potential roles of miR-425-5p in the development of HCC were investigated. The present findings demonstrated that miR-425-5p was significantly upregulated in HCC tissues and cells. miR-425-5p promoted the proliferation, migration and invasion of hepatoma cells by directly targeting and repressing FOXD3, the expression of which may suppress the malignant behavior of HCC cells. The present findings may be useful in understanding the molecular mechanisms underlying the development of HCC identifying novel treatment strategies for HCC.

Materials and methods

Clinical tissues. A total of 30 pairs of HCC tissue specimens were collected from patients who had undergone complete surgical resection at Henan Provincial People’s Hospital. Among the 30 pairs of HCC tissue specimens, 20 were hepatectomy specimens (HEPs) and adjacent nontumor tissues were immediately snap-frozen in liquid nitrogen and stored at -80˚C following surgery. Written informed consent was obtained from each patient. The study was approved by the Ethics Committee of Henan Provincial People’s Hospital. The clinical information are presented in Tables I and SI.

Cell culture and transfection. The human hepatoma cell lines HCC-LM3, Hep3B and HuH7 cells were purchased from the American Type Culture Collection. The liver cancer cell line HepG2 and liver cell line LO2 were purchased from the Chinese Academy of Sciences Cell Bank. All cells were cultured in DMEM (Invitrogen; Thermo Fisher Scientific, Inc.) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and incubated in a humidified 37˚C incubator with 5% CO2. Cell transfection was performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocols.

Plasmid construction. The potential targets of miR-425-5p were predicted using TargetScanHaman 7.2 (www.targetscan.org) and PicTar databases (pictar.mdc-berlin.de) (38,39). The FOXD3 gene was amplified from cDNA derived from HCC-LM3 cells and cloned into pcDNA3.0 (Invitrogen; Thermo Fisher Scientific, Inc.) Pfu DNA polymerase (Promega Corporation) was used to amplify cDNA, and the PCR conditions were as follows: 95˚C for 5 min, followed by 30 cycles of 94˚C for 30 sec, 58˚C for 2 min and 72˚C for 30 sec, with a final step of 72˚C for 10 min. FOXD3-specific and negative control small interfering RNA (siRNA; si-FOXD3 and si-control) were synthesized by Shanghai GenePharma Co., Ltd. miR-425-5p mimics and the antisense oligonucleotide of miR-425-5p (ASO-miR-425-5p) were commercially synthesized by Shanghai GenePharma Co., Ltd. Negative control miRNA (miR-NC) containing a scramble sequence of miRNA was used as the control for miR-425-5p mimics transfection. ASO-NC containing a scramble sequence of siRNA was used as the control for ASO-miR-425-5p. The FOXD3 3’ untranslated region (3’UTR) harboring the miR-425-5p target sequence and the seed sequence mutated type (FOXD3 3’UTR mut) were synthesized by Shanghai GenePharma Co., Ltd., and inserted into the pmiR-GLO vector (Promega Corporation). The primers and oligonucleotides used during the study are presented in Table II.

HCC-LM3 cells at a density of 70% were transfected with miR-425-5p mimics (50 nM) or ASO-miR-425-5p (100 nM), FOXD3 expressing plasmid (2 µg/well, 12-well plates; 4 µg/well, 6-well plates) or si-FOXD3 (100 nM). In the rescue experiment, cells were transfected with miR-425-5p mimics (50 nM) and FOXD3 (1 µg/well, 12-well plates). For reverse transcription-quantitative PCR (RT-qPCR), RNA was isolated 48 h following transfection.

RNA isolation and RT-qPCR. Total RNA was isolated using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocols. Briefly, for tissue samples, the tissue section was first cut into small pieces and ground in liquid nitrogen. Then, the samples were homogenized in TRIzol and RNA was extracted. cDNA was synthesized using the Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega Corporation). Briefly, 2 µg RNA with primers was incubated at 70˚C for 5 min, then the M-MLV RT enzyme, M-MLV 5X Reaction Buffer, dNTPs, RNasin (Promega Corporation) and Nuclease-Free Water were added to a final volume of 25 µl, which was incubated for 60 min at 42˚C. qPCR was performed using an SYBR Premix Ex Taq kit (Takara Biotechnology Co., Ltd.). qPCR was conducted as follows: 94˚C for 3 min, followed by 40 cycles of 94˚C for 30 sec, 56˚C for 30 sec, and 72˚C for 30 sec. GAPDH and U6 were used as internal controls for mRNA and miRNA quantification, respectively. The relative expression was calculated using the 2-ΔΔcq method (40). The primers and oligonucleotides used are listed in Table II.

Western blotting. At 48 h following transfection, cells were lysed with RIPA buffer (Beyotime Institute of Biotechnology). The protein concentrations were measured with the Bradford assay (Bio-Rad Laboratories, Inc.). Protein samples (30 µg) were separated via 10% SDS-PAGE and then transferred onto PVDF membranes. Membranes were incubated with blocking buffer (5% skim milk) at room temperature for 2 h. The membranes were then incubated overnight at 4˚C with primary antibodies against FOXD3 (1:1,000; cat. no. ab64807),
**Table I. Clinical characteristics of patients with hepatocellular carcinoma and association with miRNA-425-5p levels.**

<table>
<thead>
<tr>
<th>Clinical parameters</th>
<th>miR-425-5p high (n=19)</th>
<th>miR-425-5p low (n=11)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>11</td>
<td>6</td>
<td>0.429</td>
</tr>
<tr>
<td>≥50</td>
<td>8</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td>0.725</td>
</tr>
<tr>
<td>Male</td>
<td>15</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>TNM grade</td>
<td></td>
<td></td>
<td>0.022&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>I+II</td>
<td>14</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>III+IV</td>
<td>5</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>P<0.05. miR, microRNA.

**Table II. Primers and oligonucleotide sequences.**

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequences (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOXD3-plasmid</td>
<td>Sense: CCGGATCCATGACCTTCTCAGGGCGCGCG</td>
</tr>
<tr>
<td></td>
<td>Antisense: CGGAATTCTTAATTCGCGCGGCCATTTGGCT</td>
</tr>
<tr>
<td>FOXD3-qPCR</td>
<td>Forward: GCCCCCAACGCCTACCTTCC</td>
</tr>
<tr>
<td></td>
<td>Reverse: ATTTTCCTCCATCCCCACGG</td>
</tr>
<tr>
<td>GAPDH-qPCR</td>
<td>Forward: ATGACATCAAGAAGTTGTGTAAGCAGG</td>
</tr>
<tr>
<td></td>
<td>Reverse: GCCGTCAGAGGAGGAGTGGGT</td>
</tr>
<tr>
<td>si-FOXD3</td>
<td>Forward: ACGGGCAGGACGTGACATC</td>
</tr>
<tr>
<td></td>
<td>Reverse: GATGTCCACGTCCCTCGGGCGGT</td>
</tr>
<tr>
<td>miR-NC mimics</td>
<td>Forward: UCAACGCCUUCUAGAAAGAGUAGA</td>
</tr>
<tr>
<td></td>
<td>Reverse: UCUACUCUUUUCAGGGUUUGUA</td>
</tr>
<tr>
<td>miR-425-5p mimics</td>
<td>Forward: AAGCACAGCAUCACUCCCGUUGA</td>
</tr>
<tr>
<td></td>
<td>Reverse: UCUUCCGGUGUGUACGUCAUU</td>
</tr>
<tr>
<td>ASO-control</td>
<td>CAGUACUUUUGUAGUACAA</td>
</tr>
<tr>
<td>ASO-miR-425-5p</td>
<td>AAGACACUUUUCAGCCUUUUUUGA</td>
</tr>
<tr>
<td>mir-425-5p-RT</td>
<td>GTGATATCCAGTGCGAGTGTCAGGTGCA</td>
</tr>
<tr>
<td></td>
<td>CTGGATACGACTCTCTGGGT</td>
</tr>
<tr>
<td>U6-RT</td>
<td>AAGCCTTACAGAAATTTTGTG</td>
</tr>
<tr>
<td>miR-425-5p-qPCR</td>
<td>GCCCGCAATAGCACAGATCCTC</td>
</tr>
<tr>
<td>U6-qPCR</td>
<td>Forward: GTCGCCTCCGGACGACA</td>
</tr>
<tr>
<td></td>
<td>Reverse: GAGTATTGTCGCCAGAGGA</td>
</tr>
<tr>
<td>FOXD3 3'UTR wt</td>
<td>Forward: UCAAAAAAGCAAAAAGUGUCAUU</td>
</tr>
<tr>
<td></td>
<td>Reverse: AATGACATTCTTTGCTTTTGA</td>
</tr>
<tr>
<td>FOXD3 3'UTR mut</td>
<td>Forward: UCAAAAAAGCCAAAAACAGAUAU</td>
</tr>
<tr>
<td></td>
<td>Reverse: ATACTGTTGTTGGCTTTTGA</td>
</tr>
</tbody>
</table>

qPCR, quantitative PCR; RT, reverse transcription; miR-425-5p, microRNA-425-5p; si, small interfering RNA; ASO, antisense oligonucleotide; FOXD3, forkhead box D3; 3'UTR, 3' untranslated region; wt, wild-type; mut, mutant.

E-cadherin (1:1,000; cat. no. ab15148), Vimentin (1:1,000; cat. no. ab92547) and GAPDH (1:500; cat. no. ab181602), and then with goat anti-rabbit horseradish peroxidase-conjugated antibodies (1:1,000; cat. no. ab205718) at room temperature for 2 h. All antibodies were purchased from Abcam. GAPDH was used as an internal control. Proteins were visualized by enhanced chemiluminescence (Applygen Technologies, Inc.). LabWorks 4.0 image acquisition and analysis software was used to quantify band density (UVP, LLC).

**Luciferase reporter assay.** HCCLM3 cells were co-transfected with miR-425-5p mimics (50 nM), ASO-miR-425-5p (100 nM).
Wu et al: mir-425-5p ProMoTeS Hcc cell ProliFeraTion, MiGraTion, and in VaSion Via FOxD3

or their respective controls, and pMIR-GLO-FOXD3 3’UTR or pMIR-GLO-FOXD3 3’UTR mut reporter (100 ng/well, 24-well plates) with Lipofectamine 2000. The hRluc-neo was used as an internal control. Then, 48 h following transfection, the luciferase activities were determined using the Dual-Glo Luciferase Reporter Assay system (Promega Corporation). The results were expressed as relative luciferase activity (firefly luciferase/Renilla luciferase).

MTT assay and colony formation assay. MTT and colony formation assays were performed as previously described (41,42). Briefly, HCCLM3 cells were transfected with plasmids or oligonucleotides as aforementioned. Then, 24 h following transfection, the cells were plated in 96-well plates at a density of 3,000 cells/well. The viability of cells at 24, 48 and 72 h was evaluated using an MTT assay at 570 nm. Briefly, 10 µl MTT reagent (10 mg/ml) was added to each well prior to incubation at 37˚C for 4 h, following which 100 µl dimethyl sulfoxide was added into each well. The absorbance was detected at 570 nm using a microplate reader (BioTek instruments, inc.). cell viability was expressed as the relative a570 in experimental cells compared with in control cells [(viable cells (%)=(abs sample -absblank )/(abscontrol -absblank )x100].

Flow cytometry analysis. HCCLM3 cells were transfected as indicated and then seeded into 6-well plates (70% confluence) and cultured for 48 h. Then, the cells were collected for apoptosis analysis using an Annexin V-FITC apoptosis detection kit (BD Biosciences) according to the manufacturer's protocols. Briefly, 5 µl of Annexin V-FITC was added to a 100-µl cell solution (1x10^5 cells) and incubated at room temperature for 15 min in the dark. Then, 5 µl PI was added to the cell solution and incubated at room temperature for 15 min, before cells were washed with PBS. Cell apoptosis was evaluated using a BD FACSCalibur™ flow cytometer (BD Biosciences), and data were analyzed using FlowJo version 10 software (FlowJo LLC).

Results

miR-425-5p is upregulated in HCC tissues and cells. To study the expression profile of miR-425-5p in HCC, its expression levels were determined in 30 HCC tissues and paired adjacent nontumor tissues via RT-qPCR analysis. U6 was used as an internal control. As presented in Fig. 1A, the expression levels of miR-425-5p were significantly increased in HCC tissue compared with adjacent nontumor tissues. As presented in Table I, the expression of miR-425-5p was associated with clinical stage (P<0.01). Similarly, the levels of miR-425-5p were significantly upregulated in HCC and liver cancer cell lines (Huh7, Hep3B, HCCLM3 and HepG2) compared with a normal liver cell line (LO2; Fig. 1B). These data indicated that miR-425-5p expression was upregulated in HCC.
miR-425-5p promotes cell proliferation, migration and invasion in vitro. To investigate the roles of miR-425-5p in HCC progression, its effects on the malignant behaviors of HCC cells were determined. miR-425-5p mimics or ASO-miR-425-5p were transfected into HCCLM3 cells. RT-qPCR analysis revealed that the expression of miR-425-5p was significantly increased following transfection with miR-425-5p mimics compared with miR-NC, but was significantly decreased following ASO-miR-425-5p transfection compared with ASO-NC (Fig. 2A). MTT and colony formation assays revealed that the viability and colony formation ability of HCCLM3 cells were significantly increased when miR-425-5p was overexpressed, whereas miR-425-5p knockdown significantly decreased viability and colony formation (Fig. 2B and C). Additionally, to address whether the increase in cell proliferation was associated with cell apoptosis, flow cytometry analysis was used to evaluate the apoptosis of HCCLM3 cells. Annexin V staining revealed that the number of apoptotic cells was significantly decreased when HCCLM3 cells were transfected with miR-425-5p mimics, whereas transfection of ASO-miR-425-5p induced opposing effects (Fig. 2D). Furthermore, Transwell assays revealed that the migratory and invasive abilities of HCCLM3 cells were promoted following miR-425-5p overexpression, but were decreased by miR-425-5p knockdown (Fig. 2E and F). To determine the mechanisms underlying the effects of miR-425-5p on the migration and invasion of cells, the expression of epithelial-mesenchymal transition markers were evaluated via western blot analysis. As presented in Fig. 2G, overexpression of miR-425-5p significantly increased Vimentin expression but decreased E-cadherin expression, whereas miR-425-5p knockdown increased E-cadherin expression, but
decreased Vimentin expression. These data demonstrated that miR-425-5p promoted the proliferation, migration and invasion of HCC cells.

FOXD3 is a target of miR-425-5p in HCC cells. To investigate the underlying mechanisms by which miR-425-5p promotes HCC development, the potential targets of miR-425-5p were predicted using the TargetScan and PicTar databases. Among the predicted targets, FOXD3 was selected, as it has been reported as a tumor suppressor gene in various tumors, including HCC (29,30). Its expression in HCC tissues was determined via RT-qPCR analysis; as presented in Fig. 3a, its expression was significantly decreased in HCC tissues compared with the adjacent nontumor tissues. Bioinformatics analysis revealed that there was one putative binding site in the 3’UTR of FOXD3 mRNA (Fig. 3B). This site is conserved among vertebrates. First, a dual luciferase assay was conducted to determine whether miR-425-5p directly targets FOXD3. As presented in Fig. 3C, overexpression of miR-425-5p significantly decreased the luciferase activity of FOXD3 3’UTR (by ~60%), whereas blocking miR-425-5p markedly increased the luciferase activities of FOXD3 3’UTR (by ~50%). Conversely, when the potential binding sites for miR-425-5p in the FOXD3 3’UTR were mutated, miR-425-5p did not significantly affect the luciferase activities of FOXD3 3’UTRmut (Fig. 3C). Then, the effects of miR-425-5p on endogenous FOXD3 mRNA and protein were investigated via RT-qPCR and western blot analyses. RT-qPCR revealed that the mRNA levels of FOXD3 were significantly decreased when miR-425-5p was overexpressed, whereas knockdown of miR-425-5p resulting in opposing effects (Fig. 3D). Western blot analysis also revealed that overexpression of miR-425-5p significantly decreased, whereas knockdown of miR-425-5p increased the protein levels of FOXD3 (Fig. 3E). It was also revealed that its promoter was hypermethylated in HCC tissues and HCCLM3 cells (Table SII). These results indicated that miR-425-5p inhibits FOXD3 expression partly by binding directly to the FOXD3 3’UTR.

FOXD3 suppresses HCC cell proliferation, migration and invasion in vitro. To determine whether FOXD3 was involved in the effects of miR-425-5p on HCC cells, a FOXD3 overexpression plasmid (pcDNA3.0/FOX3D) and si-FOX3D were constructed, and the efficiency of these vectors was demonstrated by RT-qPCR and western blot analyses (Fig. 4A). The effects of FOXD3 on the malignant behaviors of HCC cells were determined. MTI and colony formation assays revealed that overexpression of FOXD3 in HCCLM3 cells significantly
decreased the viability and colony formation ability of cells, whereas knockdown of FOXD3 induced opposing effects (Fig. 4B and C). Flow cytometry analysis demonstrated that the apoptosis rate of cells was significantly increased when FOXD3 was overexpressed, but decreased following FOXD3 knockdown (Fig. 4D). Furthermore, the migratory and invasive abilities of HCCLM3 cells were significantly decreased following overexpression of FOXD3, whereas FOXD3 knockdown significantly increased the migratory and invasive abilities of HCCLM3 cells (Fig. 4E and F). Western blot analysis revealed that overexpression of FOXD3 significantly increased E-cadherin, but decreased Vimentin expression, whereas FOXD3 knockdown downregulated E-cadherin and upregulated Vimentin expression (Fig. 4G). These data indicated that FOXD3 inhibited the proliferation, migration and invasion of HCC cells.

miR-425-5p promotes HCC cell proliferation, migration and invasion via the downregulation of FOXD3 expression. However, the overexpression of FOXD3 without its 3'UTR can recover the protein levels of FOXD3. Therefore, to investigate whether the effects of miR-425-5p on the progression of HCC were mediated by downregulating FOXD3, HCCLM3 cells were co-transfected with miR-425-5p and pcdNA3.0/FoxD3, which encodes the FOXD3 coding sequence but lacks the 3'UTR. Western blot analysis revealed that transfection with FOXD3 significantly reversed the effects of miR-425-5p on FOXD3 expression (Fig. 5A). MTT and colony formation assays revealed that the restoration of FOXD3 expression significantly rescued the effects of miR-425-5p on cell viability and colony formation ability (Fig. 5B and C). Flow cytometry analysis demonstrated that the inhibition of cell apoptosis by miR-425-5p was attenuated by FOXD3 overexpression (Fig. 5D). Transwell assays revealed that the positive effects of miR-425-5p on cell migration and invasion were suppressed by FOXD3 overexpression (Fig. 5E and F). Similar results were observed for the expression of E-cadherin and Vimentin (Fig. 5G). Collectively, these results indicated that miR-425-5p promoted the proliferation, migration and invasion of HCC cells by repressing FOXD3 expression.
Discussion

It has been reported that miR-425-5p expression is dysregulated in various cancers (19-26); its expression was increased in the majority of cases, with the exception of nasopharyngeal carcinoma and melanoma. In the present study, it was observed that miR-425-5p was upregulated in HCC, consistent with a previous study (21); however, the specific mechanisms responsible for its upregulation in HCC require further exploration. Furthermore, miR-425-5p was reported to be associated with the pathogenesis and progression of numerous cancers (19-21,24,26); however, its role varies in different cancers. For example, miR-425-5p promoted cell proliferation, migration and invasion by targeting PTEN and the lysine deubiquitinase CYLD in gastric cancer (19,20). miR-425-5p promoted the invasion and metastasis of tumor cells via the suppressor of cancer cell invasion protein (Scai)-mediated dysregulation of multiple signaling pathways in HCC (21), whereas it acted as a tumor suppressor in nasopharyngeal carcinoma and melanoma cells by targeting hepatoma-derived growth factor and insulin-like growth factor 1, respectively (24,26).

miRNAs are post-transcriptional regulators that function by degrading target mRNAs or inhibiting the translation of target mRNAs. To search for targets of miR-425-5p, TargetScan and PicTar, two online software tools, were employed, which identified FOXD3 as a potential target. First, its expression was decreased in HCC tissues compared with adjacent nontumor tissues, consistent with a previous study that reported that the downregulation of FOXD3 in HCC due to promoter hypermethylation (30). It was further revealed that the promoter of FOXD3 was hypermethylated in HCC tissues and HCCLM3 cells. Whether there are other mechanisms responsible for its downregulation in HCC requires further study. Then, luciferase
expression and function (32,33). FoXd3 can also suppress cell signaling pathway, or regulating miR-214 receptor-ras-raf-mitogen activated protein kinase apoptosis of cells by inhibiting the epidermal growth factor. FoXd3 suppressed the invasive ability and inhibited the development of numerous cancers (29 -37). In colon cancer, of Twist-related protein 1, c- X-c chemokine receptor 4 and in cancer cell proliferation and migration via the regulation invasion by inhibiting the expression of the short isoform 2 of doublecortin-like kinase 1, which is a cancer stem cell marker (34). In melanoma, FoXd3 was shown to be involved double-stranded.

It was reported that FOXD3 has an important role in the development of numerous cancers (29-37). In colon cancer, FOXD3 suppressed the invasive ability and inhibited the apoptosis of cells by inhibiting the epidermal growth factor receptor-Ras-Raf-mitogen activated protein kinase kinase (MEK)-ERK signaling pathway, or regulating miR-214 expression and function (32,33). FoXd3 can also suppress cell invasion by inhibiting the expression of the short isoform 2 of doublecortin-like kinase 1, which is a cancer stem cell marker (34). In melanoma, FOXD3 was shown to be involved in cancer cell proliferation and migration via the regulation of Twist-related protein 1, C-X-C chemokine receptor 4 and paired box gene 3; its expression was controlled by MEK activity (38-40). In HCC, FOXD3 was reported to suppress cell proliferation, invasion and metastasis by regulating miR-137 expression (29). The present findings revealed similar effects on the malignant behaviors of HCC cells; however, whether miR-425-5p functions via an miR-425-5p/FoXd3/mir-137 axis or via other pathways requires further investigation.

In conclusion, the present results demonstrated that miR-425-5p was downregulated in HCC, and that miR-425 suppressed HCC cell proliferation, migration and invasion by targeting FOXD3. This study may improve understanding of the molecular mechanisms underlying HCC development, providing novel insight for the treatment of HCC.

Acknowledgements

Not applicable.

Funding

This work was supported by the Scientific and Technological Project of Henan Province (grant no. 172102310098).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

HW, JS, WZ and JL performed the experiments. HW, HN and NC analyzed and interpreted the data. HW and JS drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from each patient. The study was approved by the Ethics Committee of Henan Provincial People's Hospital.

Patient consent for approval

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


